Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer
The objective of this study was to determine if the level of serum hyaluronan (HA), serum-derived HA-associated protein (SHAP)-HA complex, and urinary trypsin inhibitor (UTI) correlate with the clinical outcome of ovarian cancer patients. The relationship of metalloproteinase and its inhibitor with...
Gespeichert in:
| Veröffentlicht in: | Oncology reports 2008-05, Vol.19 (5), p.1245-1251 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1251 |
|---|---|
| container_issue | 5 |
| container_start_page | 1245 |
| container_title | Oncology reports |
| container_volume | 19 |
| creator | OBAYASHI, Yukihiko YABUSHITA, Hiromitsu KANYAMA, Kouhei NOGUCHI, Mari LISHENG ZHUO KIMATA, Koji WAKATSUKI, Akihiko |
| description | The objective of this study was to determine if the level of serum hyaluronan (HA), serum-derived HA-associated protein (SHAP)-HA complex, and urinary trypsin inhibitor (UTI) correlate with the clinical outcome of ovarian cancer patients. The relationship of metalloproteinase and its inhibitor with HA and the SHAP-HA complex was also examined. Serum and urine samples were obtained from 45 patients with ovarian cancer, 22 patients with benign ovarian tumors and 50 healthy women. Concentrations of serum HA and UTI were measured by an inhibitory sandwich enzyme-linked immunosorbent assay, and concentrations of the serum SHAP-HA complex were measured by a sandwich enzyme-linked immunosorbent assay. Concentrations of MMP-2, MMP-9 and TIMP-1 were measured by a one-step enzyme immunoassay. The levels of HA, SHAP-HA complex, MMP-9 and TIMP-1 were higher in the ovarian cancer group than in the benign ovarian tumor group. In ovarian cancer patients, the levels of HA, SHAP-HA complex and MMP-9 were higher in the stage III/IV group than in the stage I/II group, and the levels of SHAP-HA complex, MMP-9 and TIMP-1 were higher in the non-responder group than in the responder group. The serum concentration of SHAP-HA complex had a significant correlation with HA, MMP-9 and TIMP-1 in ovarian cancer patients. The patients with elevated SHAP-HA complex had a shorter disease-free survival compared with those with normal levels of SHAP-HA complex. The multiple regression analysis revealed that SHAP-HA complex is the significant independent variable for progression-free survival. The elevated level of SHAP-HA complex may indicate the prognosis of recurrence and reflect the tumor metastasis associated with MMP-9 in ovarian cancer patients. |
| doi_str_mv | 10.3892/or.19.5.1245 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69127201</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69127201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-cf196799bc5a573d5bd75a4f5bd714b614ae6721f9e365f0eeaaf4e031fed5013</originalsourceid><addsrcrecordid>eNpFkM1LxDAQxYMo7rp68yy96MnWTNK0m6MsfsGCIAp7C2k6wUrbrMl2cf97W7e4pze8-fGYeYRcAk34XLI75xOQiUiApeKITCGXELOUw3E_UwYx52I1IWchfFHKcprJUzKBecoEn_MpWb25GiNno4C-a-ISfbXFMvrc6brzrtVtrENwptKb3l17t8GqjQ_byLhmXeNPVLWR22pfDZZuDfpzcmJ1HfBi1Bn5eHx4XzzHy9enl8X9MjZc5JvYWJBZLmVhhBY5L0VR5kKndlBIiwxSjVnOwErkmbAUUWubIuVgsRQU-Izc7HP74747DBvVVMFgXesWXRdUJoHl7A-83YPGuxA8WrX2VaP9TgFVQ5PKeQVSCTU02eNXY25XNFge4LG6HrgeAR2Mrq3v367CP8coZ1RwwX8BUsx9gw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69127201</pqid></control><display><type>article</type><title>Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>OBAYASHI, Yukihiko ; YABUSHITA, Hiromitsu ; KANYAMA, Kouhei ; NOGUCHI, Mari ; LISHENG ZHUO ; KIMATA, Koji ; WAKATSUKI, Akihiko</creator><creatorcontrib>OBAYASHI, Yukihiko ; YABUSHITA, Hiromitsu ; KANYAMA, Kouhei ; NOGUCHI, Mari ; LISHENG ZHUO ; KIMATA, Koji ; WAKATSUKI, Akihiko</creatorcontrib><description>The objective of this study was to determine if the level of serum hyaluronan (HA), serum-derived HA-associated protein (SHAP)-HA complex, and urinary trypsin inhibitor (UTI) correlate with the clinical outcome of ovarian cancer patients. The relationship of metalloproteinase and its inhibitor with HA and the SHAP-HA complex was also examined. Serum and urine samples were obtained from 45 patients with ovarian cancer, 22 patients with benign ovarian tumors and 50 healthy women. Concentrations of serum HA and UTI were measured by an inhibitory sandwich enzyme-linked immunosorbent assay, and concentrations of the serum SHAP-HA complex were measured by a sandwich enzyme-linked immunosorbent assay. Concentrations of MMP-2, MMP-9 and TIMP-1 were measured by a one-step enzyme immunoassay. The levels of HA, SHAP-HA complex, MMP-9 and TIMP-1 were higher in the ovarian cancer group than in the benign ovarian tumor group. In ovarian cancer patients, the levels of HA, SHAP-HA complex and MMP-9 were higher in the stage III/IV group than in the stage I/II group, and the levels of SHAP-HA complex, MMP-9 and TIMP-1 were higher in the non-responder group than in the responder group. The serum concentration of SHAP-HA complex had a significant correlation with HA, MMP-9 and TIMP-1 in ovarian cancer patients. The patients with elevated SHAP-HA complex had a shorter disease-free survival compared with those with normal levels of SHAP-HA complex. The multiple regression analysis revealed that SHAP-HA complex is the significant independent variable for progression-free survival. The elevated level of SHAP-HA complex may indicate the prognosis of recurrence and reflect the tumor metastasis associated with MMP-9 in ovarian cancer patients.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.19.5.1245</identifier><identifier>PMID: 18425383</identifier><language>eng</language><publisher>Athens: S.n.</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Alpha-Globulins - biosynthesis ; Alpha-Globulins - physiology ; Biological and medical sciences ; Case-Control Studies ; Disease-Free Survival ; Female ; Female genital diseases ; Gene Expression Regulation, Neoplastic ; Glycoproteins - chemistry ; Gynecology. Andrology. Obstetrics ; Humans ; Hyaluronic Acid - chemistry ; Matrix Metalloproteinase 9 - biosynthesis ; Medical sciences ; Middle Aged ; Neoplasm Metastasis ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - pathology ; Tumors</subject><ispartof>Oncology reports, 2008-05, Vol.19 (5), p.1245-1251</ispartof><rights>2008 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-cf196799bc5a573d5bd75a4f5bd714b614ae6721f9e365f0eeaaf4e031fed5013</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20320535$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18425383$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OBAYASHI, Yukihiko</creatorcontrib><creatorcontrib>YABUSHITA, Hiromitsu</creatorcontrib><creatorcontrib>KANYAMA, Kouhei</creatorcontrib><creatorcontrib>NOGUCHI, Mari</creatorcontrib><creatorcontrib>LISHENG ZHUO</creatorcontrib><creatorcontrib>KIMATA, Koji</creatorcontrib><creatorcontrib>WAKATSUKI, Akihiko</creatorcontrib><title>Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer</title><title>Oncology reports</title><addtitle>Oncol Rep</addtitle><description>The objective of this study was to determine if the level of serum hyaluronan (HA), serum-derived HA-associated protein (SHAP)-HA complex, and urinary trypsin inhibitor (UTI) correlate with the clinical outcome of ovarian cancer patients. The relationship of metalloproteinase and its inhibitor with HA and the SHAP-HA complex was also examined. Serum and urine samples were obtained from 45 patients with ovarian cancer, 22 patients with benign ovarian tumors and 50 healthy women. Concentrations of serum HA and UTI were measured by an inhibitory sandwich enzyme-linked immunosorbent assay, and concentrations of the serum SHAP-HA complex were measured by a sandwich enzyme-linked immunosorbent assay. Concentrations of MMP-2, MMP-9 and TIMP-1 were measured by a one-step enzyme immunoassay. The levels of HA, SHAP-HA complex, MMP-9 and TIMP-1 were higher in the ovarian cancer group than in the benign ovarian tumor group. In ovarian cancer patients, the levels of HA, SHAP-HA complex and MMP-9 were higher in the stage III/IV group than in the stage I/II group, and the levels of SHAP-HA complex, MMP-9 and TIMP-1 were higher in the non-responder group than in the responder group. The serum concentration of SHAP-HA complex had a significant correlation with HA, MMP-9 and TIMP-1 in ovarian cancer patients. The patients with elevated SHAP-HA complex had a shorter disease-free survival compared with those with normal levels of SHAP-HA complex. The multiple regression analysis revealed that SHAP-HA complex is the significant independent variable for progression-free survival. The elevated level of SHAP-HA complex may indicate the prognosis of recurrence and reflect the tumor metastasis associated with MMP-9 in ovarian cancer patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alpha-Globulins - biosynthesis</subject><subject>Alpha-Globulins - physiology</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Glycoproteins - chemistry</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Hyaluronic Acid - chemistry</subject><subject>Matrix Metalloproteinase 9 - biosynthesis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Tumors</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1LxDAQxYMo7rp68yy96MnWTNK0m6MsfsGCIAp7C2k6wUrbrMl2cf97W7e4pze8-fGYeYRcAk34XLI75xOQiUiApeKITCGXELOUw3E_UwYx52I1IWchfFHKcprJUzKBecoEn_MpWb25GiNno4C-a-ISfbXFMvrc6brzrtVtrENwptKb3l17t8GqjQ_byLhmXeNPVLWR22pfDZZuDfpzcmJ1HfBi1Bn5eHx4XzzHy9enl8X9MjZc5JvYWJBZLmVhhBY5L0VR5kKndlBIiwxSjVnOwErkmbAUUWubIuVgsRQU-Izc7HP74747DBvVVMFgXesWXRdUJoHl7A-83YPGuxA8WrX2VaP9TgFVQ5PKeQVSCTU02eNXY25XNFge4LG6HrgeAR2Mrq3v367CP8coZ1RwwX8BUsx9gw</recordid><startdate>20080501</startdate><enddate>20080501</enddate><creator>OBAYASHI, Yukihiko</creator><creator>YABUSHITA, Hiromitsu</creator><creator>KANYAMA, Kouhei</creator><creator>NOGUCHI, Mari</creator><creator>LISHENG ZHUO</creator><creator>KIMATA, Koji</creator><creator>WAKATSUKI, Akihiko</creator><general>S.n.</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080501</creationdate><title>Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer</title><author>OBAYASHI, Yukihiko ; YABUSHITA, Hiromitsu ; KANYAMA, Kouhei ; NOGUCHI, Mari ; LISHENG ZHUO ; KIMATA, Koji ; WAKATSUKI, Akihiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-cf196799bc5a573d5bd75a4f5bd714b614ae6721f9e365f0eeaaf4e031fed5013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alpha-Globulins - biosynthesis</topic><topic>Alpha-Globulins - physiology</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Glycoproteins - chemistry</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Hyaluronic Acid - chemistry</topic><topic>Matrix Metalloproteinase 9 - biosynthesis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>OBAYASHI, Yukihiko</creatorcontrib><creatorcontrib>YABUSHITA, Hiromitsu</creatorcontrib><creatorcontrib>KANYAMA, Kouhei</creatorcontrib><creatorcontrib>NOGUCHI, Mari</creatorcontrib><creatorcontrib>LISHENG ZHUO</creatorcontrib><creatorcontrib>KIMATA, Koji</creatorcontrib><creatorcontrib>WAKATSUKI, Akihiko</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OBAYASHI, Yukihiko</au><au>YABUSHITA, Hiromitsu</au><au>KANYAMA, Kouhei</au><au>NOGUCHI, Mari</au><au>LISHENG ZHUO</au><au>KIMATA, Koji</au><au>WAKATSUKI, Akihiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer</atitle><jtitle>Oncology reports</jtitle><addtitle>Oncol Rep</addtitle><date>2008-05-01</date><risdate>2008</risdate><volume>19</volume><issue>5</issue><spage>1245</spage><epage>1251</epage><pages>1245-1251</pages><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>The objective of this study was to determine if the level of serum hyaluronan (HA), serum-derived HA-associated protein (SHAP)-HA complex, and urinary trypsin inhibitor (UTI) correlate with the clinical outcome of ovarian cancer patients. The relationship of metalloproteinase and its inhibitor with HA and the SHAP-HA complex was also examined. Serum and urine samples were obtained from 45 patients with ovarian cancer, 22 patients with benign ovarian tumors and 50 healthy women. Concentrations of serum HA and UTI were measured by an inhibitory sandwich enzyme-linked immunosorbent assay, and concentrations of the serum SHAP-HA complex were measured by a sandwich enzyme-linked immunosorbent assay. Concentrations of MMP-2, MMP-9 and TIMP-1 were measured by a one-step enzyme immunoassay. The levels of HA, SHAP-HA complex, MMP-9 and TIMP-1 were higher in the ovarian cancer group than in the benign ovarian tumor group. In ovarian cancer patients, the levels of HA, SHAP-HA complex and MMP-9 were higher in the stage III/IV group than in the stage I/II group, and the levels of SHAP-HA complex, MMP-9 and TIMP-1 were higher in the non-responder group than in the responder group. The serum concentration of SHAP-HA complex had a significant correlation with HA, MMP-9 and TIMP-1 in ovarian cancer patients. The patients with elevated SHAP-HA complex had a shorter disease-free survival compared with those with normal levels of SHAP-HA complex. The multiple regression analysis revealed that SHAP-HA complex is the significant independent variable for progression-free survival. The elevated level of SHAP-HA complex may indicate the prognosis of recurrence and reflect the tumor metastasis associated with MMP-9 in ovarian cancer patients.</abstract><cop>Athens</cop><pub>S.n.</pub><pmid>18425383</pmid><doi>10.3892/or.19.5.1245</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1021-335X |
| ispartof | Oncology reports, 2008-05, Vol.19 (5), p.1245-1251 |
| issn | 1021-335X 1791-2431 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69127201 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Alpha-Globulins - biosynthesis Alpha-Globulins - physiology Biological and medical sciences Case-Control Studies Disease-Free Survival Female Female genital diseases Gene Expression Regulation, Neoplastic Glycoproteins - chemistry Gynecology. Andrology. Obstetrics Humans Hyaluronic Acid - chemistry Matrix Metalloproteinase 9 - biosynthesis Medical sciences Middle Aged Neoplasm Metastasis Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Tumors |
| title | Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T18%3A00%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20serum-derived%20hyaluronan-associated%20protein-hyaluronan%20complex%20in%20ovarian%20cancer&rft.jtitle=Oncology%20reports&rft.au=OBAYASHI,%20Yukihiko&rft.date=2008-05-01&rft.volume=19&rft.issue=5&rft.spage=1245&rft.epage=1251&rft.pages=1245-1251&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.19.5.1245&rft_dat=%3Cproquest_cross%3E69127201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69127201&rft_id=info:pmid/18425383&rfr_iscdi=true |